Updates to the NCCN Guidelines in multiple myeloma reflect recent trial results, giving clinicians and patients many choices.
Although the combination of bortezomib, lenalidomide, and dexamethasone remains the foundation the standard initial therapy for patients newly diagnosed with multiple myeloma (MM), the options for what to do next—including the timing of a stem cell transplant—have proliferated, and that is reflected in updates to the National Comprehensive Cancer Network (NCCN) guidelines.
At last week’s NCCN Virtual Annual Conference, Shaji K. Kumar, MD, of the Mayo Clinic Cancer Center, who chairs the guidelines committee on multiple myeloma, took the audience through key trials that inform standard treatment as well as recent ones that contributed to waves 2021 updates. NCCN moved quickly in 2020 and 2021 to add blood cancer therapies to the guidelines as soon as they met FDA muster.
Just before the conference, NCCN added melphalan flufenamide, which received FDA approval in late February to be used with dexamethasone for patients with refractory MM. The therapy received a category 2A recommendation for patients who have had at least 4 prior lines of therapy and whose disease is refractory to at least 1 proteasome inhibitor, 1 immunomodulatory agent, and 1 CD38-directed monoclonal antibody.
Kumar discussed NCCN’s addition of the Category 1 recommendation for the combination of selinexor, bortezomib, and dexamethasone. He noted that selinexor, a selective inhibitor of nuclear export given weekly, was approved by FDA in December based on the phase 3 BOSTON trial for patients who had received at least 1 prior therapy. “The BOSTON trial showed there was a clear improvement in median PFS (progression-free survival),” Kumar said.
Other recent updates recommend combinations with selinexor as “useful in certain circumstances.” Results for selinexor with daratumumab and dexamethasone appeared in November in the eJHaem, published by the British Society of Hematology. Phase 2 results for the combination with pomalidomide in heavily pretreated patients were presented at ASH; the overall response rate was 60% with deep responses, and investigators called for a phase 3 trial.
Earlier in 2021, the combination of venetoclax with dexamethasone was recommended for certain patients with translation t(11;14).
Multiple myeloma is a field where the use of triple and even quadruple therapy has exploded, and patients who have become refractory on 4 or even 5 therapies may move on to another new class or combination. Many trials involving chimeric antigen receptor (CAR) T-cell therapy are being done in MM.
Kumar said there are certain are certain settings such as high-risk myeloma, “where quadruplet therapy may be more appropriate, given the fact these regimens are associated with a higher minimal residual disease negativity, a characteristic that often appears to improve the outcomes of high risk patient population.”
He reviewed evidence that suggests for some patients, waiting for the first relapse to perform the stem cell transplant does not compromise overall survival, and can offer patients more time to make this choice.
“Now all these data from the different phase 3 trials are incorporated and have contributed to the decision-making process in terms of the guidelines,” Kumar said.
Although bortezomib/lenalidomide/dexamethasone “remains a Category 1 preferred regimen for primary therapy of transplant candidates, we have also incorporated other regimens, including carfilzomib/lenalidomide/dexamethasone as well as the quadruplets regimens,” he said.
Besides offering options for special circumstances, the guidelines now emphasize the importance of maintenance therapy, Kumar said. "Lenalidomide is a Category 1 preferred regimen for maintenance therapy in patients with newly diagnosed myeloma. Post-transplant and in patients with high risk myeloma, the general approach has been to use the combination of bortezomib and lenalidomide.”
Kumar also reviewed guidelines for managing bone lesions, cardiac and dental care, and fatigue.
New Insights on Breast Cancer Outcomes Among Sexual, Gender Minorities
December 7th 2023Despite there being a great demand for data collection on sexual orientation and gender identity in the cancer space, individuals who identify as a sexual and gender minority remain poorly represented.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Race/Ethnicity May Influence Local Recurrence in DCIS, Adjuvant Treatment
December 6th 2023Disparities in 10-year local recurrence following breast-conserving surgery were seen among women with ductal carcinoma in situ (DCIS) treated over a nearly 4-decade span at Memorial Sloan Kettering Cancer Center, with Black women having the highest rate.
Read More
SDOH in Cancer Care Highlight Multifactorial Equity Issues
December 6th 2023A trio of speakers addressed the importance of social determinants of health (SDOH) in cancer care on day 1 of the 46th annual San Antonio Breast Cancer Symposium in the session, “Social Determinants of Health: Impact on Cancer Care.”
Read More